The Department of Health and Human Services is investing more than $1.4 billion in developing next-generation vaccines and therapeutics against
Regeneron Pharmaceuticals (Nasdaq: REGN) will supply an additional 1.25M treatment courses of an antibody cocktail composed of casirivimab and imdevimab
